Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics

歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1477)

ELECTION OF LANGUAGE AND MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS

The Company is making arrangements in accordance with Rules 2.07A and 2.07B of the Listing Rules and the Articles of Association, to offer the Shareholders the options to elect for the language(s) and means of receipt of the Company's future Corporate Communications.

INTRODUCTION

The Company hereby announces that pursuant to Rules 2.07A and 2.07B of the Listing Rules and the Articles of Association, arrangements have been made to offer the Shareholders the options to elect for the language(s) (in English only, in Chinese only or in both English and Chinese) of the Company's future Corporate Communications and the means of receipt (in printed form or by Website Version).

In support of environmental protection and saving of printing and mailing costs, the Company recommends the Shareholders to elect for the Website Version for receiving the Company's future Corporate Communications.

ARRANGEMENTS

In accordance with Rules 2.07A and 2.07B of the Listing Rules and the Articles of Association, the following arrangements have been made by the Company:

- 1. The First Letter dated September 30, 2020 will be sent by the Company together with the Reply Form, in both English and Chinese, to the Shareholders to enable them to elect for any one of the following options:
 - (i) to read the Website Version of all future Corporate Communications instead of receiving printed copies, and to receive a printed notification letter of the publication of the Corporate Communications on the Company's Website by post; or
 - (ii) to receive the printed English version of all future Corporate Communications by post only; or
 - (iii) to receive the printed Chinese version of all future Corporate Communications by post only; or

(iv) to receive both the printed English and Chinese versions of all future Corporate Communications by post.

The Reply Form should be completed, signed and returned by post using the mailing label at the bottom of the Reply Form or by hand delivery to the Company c/o the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, on or before October 28, 2020.

The First Letter explains that if the Company does not receive the Reply Form or a response indicating any objection from the Shareholder on or before October 28, 2020 and until the Shareholder informs the Company c/o the Share Registrar by reasonable prior notice in writing or by sending an email to ocumension.ecom@computershare.com.hk, such Shareholder will be deemed to have consented to receive the Website Version, and a notification letter of the publication of the Corporate Communications on the Company's Website will be sent to such Shareholder in the future.

- 2. Shareholders who wish to receive the Corporate Communications in printed form can select to receive either the English version only, or the Chinese version only, or both English and Chinese versions. The Company will send the selected language version(s) of the Corporate Communications to those Shareholders who have made a selection unless and until they inform the Company c/o the Share Registrar by reasonable prior notice in writing or by sending an email to ocumension.ecom@computershare.com.hk that they wish to receive the Corporate Communications in the other (or both) language(s) (as the case may be), or by the Website Version.
- 3. When each of the printed future Corporate Communications is sent in accordance with the arrangements described above, the Second Letter together with the Change Request Form, in both English and Chinese, will be attached to or printed at some prominent place in the relevant Corporate Communications, specifying that the Corporate Communications prepared in the other language will be available upon request. Shareholders may at any time request for the other language of the Corporate Communications by completing and returning the Change Request Form to the Company c/o the Share Registrar or by sending an email to ocumension.ecom@computershare.com.hk.
- 4. For those Shareholders who choose, or are deemed to have consented, to receive the Website Version, if for any reason, such Shareholders have difficulty in gaining access to the Company's Website or wish to receive a printed version, the Company will upon request in writing to the Company c/o the Share Registrar or by email to ocumension.ecom@computershare.com.hk promptly send the relevant Corporate Communications to such Shareholders in printed form free of charge.
- 5. All future Corporate Communications in both English and Chinese and in accessible format will be available on the Company's Website at www.ocumension.com and the Stock Exchange's website at www.hkexnews.hk.

- 6. Shareholders shall have the right at any time by reasonable prior notice in writing to the Company c/o the Share Registrar or by sending a prior notice via email at ocumension.ecom@computershare.com.hk specifying their name, address and request, to change the means of receipt and/or the language of the Corporate Communications.
- 7. Shareholders can call the hotline of the Share Registrar at (852) 2862 8688 during business hours (9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding public holidays) in respect of any queries in relation to the Company's arrangements set out above.
- 8. The First Letter and the Second Letter mention that both languages of future Corporate Communications will be available from the Company and the Share Registrar upon request, as well as on the Company's Website and on the Stock Exchange's website, and that the dial-up hotline service has been provided.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the meanings set out below:

"Articles of Association"	the amended and restated articles of association of the Company
	conditionally adopted on June 23, 2020 and effective on July 10, 2020,
	as amended from time to time

"Change Request Form"	a pre-paid Change Request Form (a stamp is not needed for posting in
	Hong Kong) to be sent together with the Second Letter

"Company"	Ocumension Therapeutics, a company incorporated under the laws of
	the Cayman Islands with limited liability on February 27, 2018

"Company's Website"	www.ocumension.com

"Corporate Communications"	documents issued or to be issued by the Company for the information or action of holders of any of the Company's securities or the investing public as defined in Rule 1.01 of the Listing Rules, including but not
	limited to: (a) annual reports and its summary financial reports (where
	applicable)(and all reports and accounts contained therein); (b) the
	interim reports and its summary interim reports (where applicable)(and
	all reports and accounts contained therein); (c) notices of meeting; (d)
	listing documents; (e) circulars and (f) forms of proxy

"First Letter"	a letter dated September 30, 2020 to be sent by the Company to the
	Shareholders together with the Reply Form

"Stock Exchange"	The Stock Exchange of Hong Kong Limited
------------------	---

"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic
	of China

"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange
	of Hong Kong Limited

"Reply Form" a pre-paid reply form (a stamp is not needed for posting in Hong Kong)

to be sent together with the First Letter

"Second Letter" a letter to be sent to the Shareholders by the Company together with

each future printed Corporate Communications and the Change Request

Form

"Share Registrar" Computershare Hong Kong Investor Services Limited at 17M Floor,

Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong

"Shareholder(s)" Holder(s) of the shares of the Company

"Website Version" the version of Corporate Communications published in electronic form,

in both English and Chinese, on the Company's Website

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Executive Director

Shanghai, the People's Republic of China, September 30, 2020

As of the date of this announcement, the board of directors of the Company comprises Dr. Lian Yong CHEN as Chairman and executive director, Mr. Ye LIU, Dr. Zhaopeng HU and Dr. Wei LI as executive directors, Mr. Yanling CAO and Mr. Lefei SUN as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE, and Mr. Yiran HUANG as independent non-executive directors.